scholarly journals Photon-deficient Mass on FDG-PET Scan in Renal Cell Carcinoma: A Case Report

2008 ◽  
Vol 2 ◽  
pp. CCRep.S724
Author(s):  
George Shih ◽  
Wei-Jen Shih ◽  
Bonnie Mitchell ◽  
Primo P Milan
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Fdg Pet ◽  
Renal Cell ◽  
Positron Emission Tomography Imaging ◽  
Imaging Study ◽  
Positron Emission ◽  
Fdg Pet Scan ◽  
The Right

F-18 Fluorodeoxyglucose Positron Emission Tomography imaging (F-18 FDG PET) detects malignancies depending on the uptake profile of glycolysis of tumors; however, the role of FDG PET is limited in the evaluation of primary renal malignancy because of low FDG uptake by renal cell carcinoma and also because normal urinary excretion of FDG seen in the images. A patient with renal cell carcinoma whose FDG PET imaging study incidentally shows a photon-deficient mass in the upper pole of the right kidney is present here. The diagnosis is also validated by the histopathological findings of tumor necrosis, hemorrhage, and scars.

Clinical role of early dynamic FDG-PET/CT for the evaluation of renal cell carcinoma

2015 ◽  
Vol 26 (6) ◽  
pp. 1852-1862 ◽  
Author(s):  
Reiko Nakajima ◽  
Koichiro Abe ◽  
Tsunenori Kondo ◽  
Kazunari Tanabe ◽  
Shuji Sakai
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Fdg Pet ◽  
Renal Cell ◽  
Clinical Role ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma

2014 ◽  
Vol 48 (3) ◽  
pp. 219-227 ◽  
Author(s):  
Carmelo Caldarella ◽  
Barbara Muoio ◽  
Maria Antonietta Isgrò ◽  
Emilio Porfiri ◽  
Giorgio Treglia ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Kinase Inhibitors ◽  
Response Assessment ◽  
Emission Tomography ◽  
Positron Emission ◽  
Pet Ct

Abstract Background. Positron emission tomography-computed tomography (PET-CT) using fluorodeoxyglucose (FDG) is increasingly used in the evaluation of patients with advanced renal cell carcinoma (RCC), primarily for staging purposes. The aim of this paper is to perform a systematic review about the usefulness of PET-CT using FDG in response assessment after treatment with tyrosine-kinase inhibitors (TKIs) in patients with advanced RCC. Materials and methods. The scientific literature about the role of PET-CT using FDG in the assessment of response to treatment with TKIs in patients affected by advanced RCC was systematically reviewed. Results. Seven studies about the role of PET-CT using FDG in the response assessment after treatment with TKIs (essentially sunitinib and sorafenib) in advanced RCC were retrieved in full-text and analysed, to determine the predictive role of this morpho-functional imaging method on patient outcome. Conclusions. To date, the role of PET-CT using FDG in evaluating the response to TKIs in metastatic RCC patients is still not well defined, partly due to heterogeneity of available studies; however, PET-CT reveals potential role for the selection of patients undergoing therapy with TKIs. The use of contrast-enhanced PET-CT appears to be promising for a “multi-dimensional” evaluation of treatment response in these patients.

Sign in / Sign up

Export Citation Format

Share Document